Read previous post:
Dr. Yves Fradet, President of Diagnocure. On Wednesday, Byron Capital analyst Douglas Loe upgraded the company to Buy from Speculative Buy because he says Diagnocure is no longer as subject to clinical or regulatory risk.
Byron Capital’s Douglas Loe Raises Target Price on Diagnocure

This past Wednesday DiagnoCure (TSX:CUR), along with its US-based partner Gen-Probe, received FDA approval for its lead prostate cancer diagnostic...